Quality of life and inflammation in exacerbations of bronchiectasis

JM Courtney, MG Kelly, A Watt, L Garske, J Bradley, M Ennis, JS Elborn

    Research output: Contribution to journalArticle

    37 Citations (Scopus)

    Abstract

    Patients with bronchiectasis often have impaired quality of life (QoL), which deteriorates with exacerbations. The aim of this study was to investigate changes in QoL and how these were influenced by changes in airway physiology and inflammation in patients with bronchiectasis before and after resolution of an exacerbation. Sputum induction and a QoL questionnaire were undertaken on the first day, day 14, and 4 weeks after completion of intravenous antibiotics (day 42). Eighteen patients (12 female) were recruited, median (IQ range) age of 54 (47–60) years. There was a trend towards an improvement in lung function from visit 1 to visit 2, but this was not statistically significant. C-reactive protein (CRP) [mean (SEM)] reduced between visit 1 and visit 2 [55.4 (21.5) vs 9.4 (3.1) mg/L, P = 0.03] but did not increase significantly on visit 3 [44.4 32.9) mg/L, P = 0.27]. The median (interquartile range) sputum cell count (×106 cells/g of sputum) decreased from visit 1 to visit 2 [21.6 (11.8–37.6)–13.3 (6.7–22.9) × 106 cells/g, respectively, P = 0.008] and increased from visit 2 to visit 3 [26.3 (14.1–33.6) × 106 cells/g, P = 0.03]. All solublemarkers of inflammation significantly reduced from visit 1 to visit 2 but increased on visit 3 with the exception of TNF-α. Regarding QoL, three of the four domains (dyspnoea, emotional, mastery) significantly improved from visit 1 to visit 2 but did not change between visit 2 and visit 3. The improvements in QoL scores could not be explained by the improvements in lung function or inflammatory markers.
    LanguageEnglish
    Pages161-168
    JournalChronic Respiratory Disease
    Volume5
    Issue number3
    DOIs
    Publication statusPublished - 2008

    Fingerprint

    Bronchiectasis
    Quality of Life
    Inflammation
    Sputum
    Lung
    Dyspnea
    C-Reactive Protein
    Tumor Necrosis Factor-alpha
    Cell Count
    Anti-Bacterial Agents

    Keywords

    • bronchiectasis
    • exacerbation
    • inflammation
    • quality of life

    Cite this

    Courtney, JM., Kelly, MG., Watt, A., Garske, L., Bradley, J., Ennis, M., & Elborn, JS. (2008). Quality of life and inflammation in exacerbations of bronchiectasis. Chronic Respiratory Disease, 5(3), 161-168. https://doi.org/10.1177/1479972308091823
    Courtney, JM ; Kelly, MG ; Watt, A ; Garske, L ; Bradley, J ; Ennis, M ; Elborn, JS. / Quality of life and inflammation in exacerbations of bronchiectasis. In: Chronic Respiratory Disease. 2008 ; Vol. 5, No. 3. pp. 161-168.
    @article{056732b63a834985b52271367ee687f0,
    title = "Quality of life and inflammation in exacerbations of bronchiectasis",
    abstract = "Patients with bronchiectasis often have impaired quality of life (QoL), which deteriorates with exacerbations. The aim of this study was to investigate changes in QoL and how these were influenced by changes in airway physiology and inflammation in patients with bronchiectasis before and after resolution of an exacerbation. Sputum induction and a QoL questionnaire were undertaken on the first day, day 14, and 4 weeks after completion of intravenous antibiotics (day 42). Eighteen patients (12 female) were recruited, median (IQ range) age of 54 (47–60) years. There was a trend towards an improvement in lung function from visit 1 to visit 2, but this was not statistically significant. C-reactive protein (CRP) [mean (SEM)] reduced between visit 1 and visit 2 [55.4 (21.5) vs 9.4 (3.1) mg/L, P = 0.03] but did not increase significantly on visit 3 [44.4 32.9) mg/L, P = 0.27]. The median (interquartile range) sputum cell count (×106 cells/g of sputum) decreased from visit 1 to visit 2 [21.6 (11.8–37.6)–13.3 (6.7–22.9) × 106 cells/g, respectively, P = 0.008] and increased from visit 2 to visit 3 [26.3 (14.1–33.6) × 106 cells/g, P = 0.03]. All solublemarkers of inflammation significantly reduced from visit 1 to visit 2 but increased on visit 3 with the exception of TNF-α. Regarding QoL, three of the four domains (dyspnoea, emotional, mastery) significantly improved from visit 1 to visit 2 but did not change between visit 2 and visit 3. The improvements in QoL scores could not be explained by the improvements in lung function or inflammatory markers.",
    keywords = "bronchiectasis, exacerbation, inflammation, quality of life",
    author = "JM Courtney and MG Kelly and A Watt and L Garske and J Bradley and M Ennis and JS Elborn",
    year = "2008",
    doi = "10.1177/1479972308091823",
    language = "English",
    volume = "5",
    pages = "161--168",
    journal = "Chronic Respiratory Disease",
    issn = "1479-9723",
    number = "3",

    }

    Courtney, JM, Kelly, MG, Watt, A, Garske, L, Bradley, J, Ennis, M & Elborn, JS 2008, 'Quality of life and inflammation in exacerbations of bronchiectasis', Chronic Respiratory Disease, vol. 5, no. 3, pp. 161-168. https://doi.org/10.1177/1479972308091823

    Quality of life and inflammation in exacerbations of bronchiectasis. / Courtney, JM; Kelly, MG; Watt, A; Garske, L; Bradley, J; Ennis, M; Elborn, JS.

    In: Chronic Respiratory Disease, Vol. 5, No. 3, 2008, p. 161-168.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Quality of life and inflammation in exacerbations of bronchiectasis

    AU - Courtney, JM

    AU - Kelly, MG

    AU - Watt, A

    AU - Garske, L

    AU - Bradley, J

    AU - Ennis, M

    AU - Elborn, JS

    PY - 2008

    Y1 - 2008

    N2 - Patients with bronchiectasis often have impaired quality of life (QoL), which deteriorates with exacerbations. The aim of this study was to investigate changes in QoL and how these were influenced by changes in airway physiology and inflammation in patients with bronchiectasis before and after resolution of an exacerbation. Sputum induction and a QoL questionnaire were undertaken on the first day, day 14, and 4 weeks after completion of intravenous antibiotics (day 42). Eighteen patients (12 female) were recruited, median (IQ range) age of 54 (47–60) years. There was a trend towards an improvement in lung function from visit 1 to visit 2, but this was not statistically significant. C-reactive protein (CRP) [mean (SEM)] reduced between visit 1 and visit 2 [55.4 (21.5) vs 9.4 (3.1) mg/L, P = 0.03] but did not increase significantly on visit 3 [44.4 32.9) mg/L, P = 0.27]. The median (interquartile range) sputum cell count (×106 cells/g of sputum) decreased from visit 1 to visit 2 [21.6 (11.8–37.6)–13.3 (6.7–22.9) × 106 cells/g, respectively, P = 0.008] and increased from visit 2 to visit 3 [26.3 (14.1–33.6) × 106 cells/g, P = 0.03]. All solublemarkers of inflammation significantly reduced from visit 1 to visit 2 but increased on visit 3 with the exception of TNF-α. Regarding QoL, three of the four domains (dyspnoea, emotional, mastery) significantly improved from visit 1 to visit 2 but did not change between visit 2 and visit 3. The improvements in QoL scores could not be explained by the improvements in lung function or inflammatory markers.

    AB - Patients with bronchiectasis often have impaired quality of life (QoL), which deteriorates with exacerbations. The aim of this study was to investigate changes in QoL and how these were influenced by changes in airway physiology and inflammation in patients with bronchiectasis before and after resolution of an exacerbation. Sputum induction and a QoL questionnaire were undertaken on the first day, day 14, and 4 weeks after completion of intravenous antibiotics (day 42). Eighteen patients (12 female) were recruited, median (IQ range) age of 54 (47–60) years. There was a trend towards an improvement in lung function from visit 1 to visit 2, but this was not statistically significant. C-reactive protein (CRP) [mean (SEM)] reduced between visit 1 and visit 2 [55.4 (21.5) vs 9.4 (3.1) mg/L, P = 0.03] but did not increase significantly on visit 3 [44.4 32.9) mg/L, P = 0.27]. The median (interquartile range) sputum cell count (×106 cells/g of sputum) decreased from visit 1 to visit 2 [21.6 (11.8–37.6)–13.3 (6.7–22.9) × 106 cells/g, respectively, P = 0.008] and increased from visit 2 to visit 3 [26.3 (14.1–33.6) × 106 cells/g, P = 0.03]. All solublemarkers of inflammation significantly reduced from visit 1 to visit 2 but increased on visit 3 with the exception of TNF-α. Regarding QoL, three of the four domains (dyspnoea, emotional, mastery) significantly improved from visit 1 to visit 2 but did not change between visit 2 and visit 3. The improvements in QoL scores could not be explained by the improvements in lung function or inflammatory markers.

    KW - bronchiectasis

    KW - exacerbation

    KW - inflammation

    KW - quality of life

    U2 - 10.1177/1479972308091823

    DO - 10.1177/1479972308091823

    M3 - Article

    VL - 5

    SP - 161

    EP - 168

    JO - Chronic Respiratory Disease

    T2 - Chronic Respiratory Disease

    JF - Chronic Respiratory Disease

    SN - 1479-9723

    IS - 3

    ER -

    Courtney JM, Kelly MG, Watt A, Garske L, Bradley J, Ennis M et al. Quality of life and inflammation in exacerbations of bronchiectasis. Chronic Respiratory Disease. 2008;5(3):161-168. https://doi.org/10.1177/1479972308091823